EMA. European Medicines Agency (EMA) - Quality of medicines questions and answers: Part 1. 2022. https://www.ema.europa.eu/en/human-regulatory/research-development/scientific-guidelines/qa-quality/quality-medicines-questions-answers-part-1#variation-section. Accessed 3 Apr 2022.

EMA. European Medicines Agency (EMA) - Guideline on process validation for finished products - information and data to be provided in regulatory submissions. 2016. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-process-validation-finished-products-information-data-be-provided-regulatory-submissions_en.pdf. Accessed 22 Apr 2022.

EMA. European Medicines Agency (EMA) - Quality guidelines. 2022. https://www.ema.europa.eu/en/human-regulatory/research-development/scientific-guidelines/quality-guidelines. Accessed 3 Apr 2022.

EMA. European Medicines Agency (EMA) - Quality guidelines: specific types of products. 2022. https://www.ema.europa.eu/en/human-regulatory/research-development/scientific-guidelines/quality/quality-specific-types-products. Accessed 3 Apr 2022.

EMA. European Medicines Agency (EMA) - Multidisciplinary quality guidelines: nanomedicines. 2022. https://www.ema.europa.eu/en/human-regulatory/research-development/scientific-guidelines/multidisciplinary/multidisciplinary-nanomedicines. Accessed 3 Apr 2022.

EC. European Commission (EC) - Annex 1: Clinical trial application form request for authorisation of a clinical trial on a medicinal product for human use to the competent authorities and for opinion of the ethics committees in the community (revision 4 of November 2009; updated on 22 of November 2019). 2019. https://ec.europa.eu/health/system/files/2019-11/application-form_en_0.pdf. Accessed 3 Apr 2022.

Regulation (EU) No 536/2014. 2014. Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on Clinical Trials on Medicinal Products for Human Use, and Repealing Directive 2001/20/EC. 2014. https://eur-lex.europa.eu/eli/reg/2014/536/oj. Accessed 3 Apr 2022.

CTIS. Clinical Trials Information System (CTIS) - Clinical trials in the European Union. 2022. https://euclinicaltrials.eu/home. Accessed 3 Apr 2022.

EMA. European Medicines Agency (EMA) - Marketing Authorisation Application (MAA) Pre-submission meeting request form. 13 October 2020, EMA/571057/2010. 2020. https://www.ema.europa.eu/documents/template-form/marketing-authorisation-application-maa-pre-submission-meeting-request-form-human_en.docx. Accessed 3 Apr 2022.

Clinicaltrials.gov. 2022. https://clinicaltrials.gov. Accessed 3 Apr 2022.

EU Clinical Trials Register. 2022. https://www.clinicaltrialsregister.eu. Accessed 3 Apr 2022.

FDA. Food and Drug Administration (FDA) - Nanotechnology - Over a Decade of Progress and Innovation. A report by the U.S. Food and Drug Administration. 2020. https://www.fda.gov/media/140395/download. Accessed 3 Apr 2022.

Anselmo AC, Mitragotri S. Nanoparticles in the clinic: An update. Bioeng Transl Med. 2019;4(3):e10143. https://doi.org/10.1002/btm2.10143.

Article  PubMed  PubMed Central  Google Scholar 

Farjadian F, Ghasemi A, Gohari O, Roointan A, Karimi M, Hamblin MR. Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities. Nanomedicine. 2019;14:93–126. https://doi.org/10.2217/nnm-2018-0120.

Article  CAS  PubMed  Google Scholar 

Vencken SF, Greene CM. Chapter 15 - A review of the regulatory framework for nanomedicines in the European Union. In: Inorganic Frameworks as Smart Nanomedicines. William Andrew Publishing; 2018. p. 641–79. https://doi.org/10.1016/B978-0-12-813661-4.00015-8.

Chapter  Google Scholar 

Choi YH, Han HK. Nanomedicines: current status and future perspectives in aspect of drug delivery and pharmacokinetics. J Pharm Investig. 2018;48:43–60. https://doi.org/10.1007/s40005-017-0370-4.

Article  CAS  PubMed  Google Scholar 

Coty J-B, Vauthier C. Characterization of nanomedicines: A reflection on a field under construction needed for clinical translation success. J Control Release. 2018;275:254–68. https://doi.org/10.1016/j.jconrel.2018.02.013.

Article  CAS  PubMed  Google Scholar 

Hua S, de Matos MBC, Metselaar JM, Storm G. Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization. Front Pharmacol. 2018;9:790. https://doi.org/10.3389/fphar.2018.00790.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Milane L, Amiji M. Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine. Drug Deliv and Transl Res. 2021;11:1309–15. https://doi.org/10.1007/s13346-021-00911-y.

Article  CAS  Google Scholar 

Younis MA, Tawfeek HM, Abdellatif AAH, Abdel-Aleem JA, Harashima H. Clinical translation of nanomedicines: Challenges, opportunities, and keys. Adv Drug Deliv Rev. 2022;181:114083. https://doi.org/10.1016/j.addr.2021.114083.

Article  CAS  PubMed  Google Scholar 

Halamoda-Kenzaoui B, Vandebriel RJ, Howarth A, et al. Methodological needs in the quality and safety characterisation of nanotechnology-based health products: Priorities for method development and standardisation. J Control Release. 2021;336:192–206. https://doi.org/10.1016/j.jconrel.2021.06.016.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shan X, Gong X, Li J, Wen J, Li Y, Zhang Z. Current approaches of nanomedicines in the market and various stage of clinical translation. Acta Pharm Sin B. 2022;12(7):3028–48. https://doi.org/10.1016/j.apsb.2022.02.025.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Refine Project. Regulatory Science Framework for Nano(bio)material-based Medical Products and Devices. http://refine-nanomed.eu/. Accessed 7 Nov 2022.

Foulkes R, Man E, Thind J, Yeung S, Joy A, Hoskins C. The regulation of nanomaterials and nanomedicines for clinical application: current and future perspectives. Biomater Sci. 2020;8:4653–64. https://doi.org/10.1039/D0BM00558D.

Article  CAS  PubMed  Google Scholar 

EC. European Commission (EC) - Nanomaterials: Commission proposes case by case approach to assessment (3 October 2012). 2012. https://ec.europa.eu/commission/presscorner/api/files/document/print/en/memo_12_732/MEMO_12_732_EN.pdf. Accessed 3 Apr 2022.

EC. European Commission (EC) - Scientific Committee on Emerging and Newly Identified Health Risks (2009). 19 January 2009. Risk Assessment of Products of Nanotechnologies. 2009. https://ec.europa.eu/health/ph_risk/committees/04_scenihr/docs/scenihr_o_023.pdf. Accessed 3 Apr 2022.

EC. European Commission (EC) - Scientific Committee on Emerging and Newly Identified Health Risks (2014). 10 -11 June 2014. Opinion on Nanosilver: safety, health and environmental effects and role in antimicrobial resistance. 2014. https://ec.europa.eu/health/scientific_committees/emerging/docs/scenihr_o_039.pdf. Accessed 3 Apr 2022.

EMA. European Medicines Agency (EMA). EMEA/CHMP/79769/2006. Reflection paper on nanotechnology-based medicinal products for human use. 2006. https://etp-nanomedicine.eu/wp-content/uploads/2018/10/reflection-paper-nanotechnology-based-medicinal-products-human-use_en-1.pdf. Accessed 3 Apr 2022.

EMA. European Medicines Agency (EMA). EMA/CHMP/QWP/799402/2011. Reflection Paper on the Pharmaceutical Development of Intravenous Medicinal Products Containing Active Substances Solubilised in Micellar Systems. 2012. https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-pharmaceutical-development-intravenous-medicinal-products-containing-active_en.pdf. Accessed 3 Apr 2022.

EMA. European Medicines Agency (EMA). EMA/CHMP/13099/2013. Joint MHLW/EMA reflection paper on the development of block copolymer micelle medicinal products. 2013. https://www.ema.europa.eu/en/documents/scientific-guideline/joint-mhlw/ema-reflection-paper-development-block-copolymer-micelle-medicinal-products_en.pdf. Accessed 3 Apr 2022.

EMA. European Medicines Agency (EMA). EMA/CHMP/806058/2009/Rev. 02. Reflection paper on the data requirements for intravenous liposomal products developed with reference to an innovator liposomal product. 2013. https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-data-requirements-intravenous-liposomal-products-developed-reference-innovator_en.pdf. Accessed 3 Apr 2022.

EMA. European Medicines Agency (EMA). EMA/325027/2013. Reflection paper on surface coatings: general issues for consideration regarding parenteral administration of coated nanomedicine products. 2013. https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-surface-coatings-general-issues-consideration-regarding-parenteral-administration_en.pdf. Accessed 3 Apr 2022.

EMA. European Medicines Agency (EMA). EMA/CHMP/SWP/620008/2012. Reflection paper on the data requirements for intravenous iron-based nano-colloidal products developed with reference to an innovator medicinal product. 2015. https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-data-requirements-intravenous-iron-based-nano-colloidal-products-developed_en.pdf. Accessed 3 Apr 2022.

EMA. European Medicines Agency (EMA). EMA/484400/2014. Mandate of the EMA Innovation Task Force (ITF). 2014. https://www.ema.europa.eu/en/documents/other/mandate-european-medcines-agency-innovation-task-force-itf_en.pdf. Accessed 3 Apr 2022.

EMA. European Medicines Agency (EMA). EMA/CHMP/QWP/545525/2017 Rev. 2. Committee for Medicinal Products for Human Use (CHMP) - Guideline on the requirements for the chemical and pharmaceutical quality documentation concerning investigational medicinal products in clinical trials. 2022. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-requirements-chemical-pharmaceutical-quality-documentation-concerning-investigational_en-1.pdf. Accessed 3 Apr 2022.

EMA. European Medicines Agency (EMA). EMA/CHMP/BWP/534898/2008 Rev. 2. Committee for Medicinal Products for Human Use (CHMP) - Guideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials. 2022. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-requirements-quality-documentation-concerning-biological-investigational-medicinal_en-2.pdf. Accessed 3 Apr 2022.

Musazzi UM, Marini V, Casiraghi A, Minghetti P. Is the European regulatory framework sufficient to assure the safety of citizens using health products containing nanomaterials? Drug Discov Today. 2017;22:870–82. https://doi.org/10.1016/j.drudis.2017.01.016.

Article  PubMed  Google Scholar 

FDA. Food and Drug Administration (FDA) - Guidance for Industry CGMP for Phase 1 Investigational Drugs. 2008. https://www.fda.gov/media/70975/download. Accessed 3 Apr 2022.

FDA. Food and Drug Administration (FDA) - FDA’s guidance for industry Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-derived Products. 1995. https://www.fda.gov/media/71203/download. Accessed 3 Apr 2022.

FDA. Food and Drug Administration (FDA) - Guidance for Industry - INDs for Phase 2 and Phase 3 Studies Chemistry, Manufacturing, and Controls Information. 2003. https://www.fda.gov/media/70822/download. Accessed 3 Apr 2022.

FDA. Food and Drug Administration (FDA) - Guidance for Industry Considering Whether an FDA-Regulated Product Involves the Application of Nanotechnology. 2014. https://www.fda.gov/media/88423/download. Accessed 3 Apr 2022.

FDA. Food and Drug Administration (FDA) - Draft Guidance - Drug Products, Including Biological Products, that Contain Nanomaterials. Guidance for Industry. 2022. https://www.fda.gov/media/157812/download. Accessed 13 Oct 2022.

FDA. Food and Drug Administration (FDA) - Liposome Drug Products Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation. Guidance for Industry. 2018. https://www.fda.gov/media/70837/download. Accessed 3 Apr 2022.

PMDA. Pharmaceuticals and Medical Devices Agency. Nanomedicine Initiative Working Group. 2013. https://www.pmda.go.jp/english/rs-sb-std/rs/0010.html. Accessed 3 Apr 2022.

MHLW. Ministry of Health, Labour and Welfare (MHLW) - Reflection paper on nucleic acids (siRNA)-loaded nanotechnology-based drug products. 2016. https://www.nihs.go.jp/drug/section4/160328_MHLW_siRNA_RP.pdf. Accessed 3 Apr 2022.

MHLW. Ministry of Health, Labour and Welfare (MHLW) - Guideline for the Development of Liposome Drug Products. 2016. https://www.nihs.go.jp/drug/section4/160328_MHLW_liposome_guideline.pdf. Accessed 3 Apr 2022.

HC. Health Canada (HC) - Current Issues with Nanomedicines in Canada. 2010. https://www.ema.europa.eu/en/documents/presentation/presentation-nanomedicines-current-initiatives-canada-duc-vu-health-canada_en.pdf. Accessed 3 Apr 2022.

HC. Health Canada (HC) - Policy Statement on Health Canada's Working Definition for Nanomaterial. 2011. https://www.canada.ca/en/health-canada/services/science-research/reports-publications/nanomaterial/policy-statement-health-canada-working-definition.html. version 2. Accessed 3 April 2022.

HC. Health Canada (HC) - Frequently Asked Questions Related to the Policy Statement on Health Canada's Working Definition for Nanomaterial. 2011. https://www.canada.ca/en/health-canada/services/science-research/reports-publications/nanomaterial/policy-statement-working-definition-nanomaterial-frequently-asked-questions.html#a16. Accessed 3 Apr 2022.

DBT. Department of Biotechnology Government of India (DBT), New Delhi - Guidelines for Evaluation of Nanopharmaceuticals in India, Department of Biotechnology Government of India. 2019. http://dbtindia.gov.in/sites/default/files/uploadfiles/Guidelines_For_Evaluation_of_Nanopharmaceuticals_in_India_24.10.19.pdf. Accessed 3 Apr 2022.

EC. European Commission (EC), Joint Research Centre, Halamoda-Kenzaoui B, Box H, van Elk M, Gaitan S, Geertsma RE, Gainza Lafuente E, Owen A, Del Pozo A, Roesslein M, Bremer-Hoffmann S. Anticipation of regulatory needs for nanotechnology-enabled health products. Luxembourg: Publications Office of the European Union; 2019. https://doi.org/10.2760/596822. EUR 29919 EN; ISBN 978-92-76-12554-9.

Book  Google Scholar 

Ge X, Wei M, He S, Yuan W. Advances of Non-Ionic Surfactant Vesicles (Niosomes) and Their Application in Drug Delivery. Pharmaceutics. 2019;11(2):55. https://doi.org/10.3390/pharmaceutics11020055.

Article  CAS  PubMed  PubMed Central  Google Scholar 

EMA. European Medicines Agency (EMA) - EMA/CHMP/ICH/167068/2004 - Committee for Human Medicinal Products ICH guideline Q8 (R2) on pharmaceutical development, Step 5. 2017. https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use_en-11.pdf. Accessed 3 Apr 2022.

EC. European Commission (EC), Joint Research Centre, Quirós Pesudo L, Balahur A, Gottardo S, Rasmussen K, Wagner G, Joanny G, Bremer-Hoffmann S. Mapping Nano-medicine Terminology in the Regulatory Landscape. Luxembourg: Publications Office of the European Union; 2018. https://doi.org/10.2760/753829. ISBN 978-92-79-89872-3.

Book  Google Scholar 

EC. European Commission (EC) - Commission Recommendation of 18 October 2011 on the definition of nanomaterial, text with EEA relevance (2011/696/EU). 2011. https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32011H0696&from=EN. Accessed 3 Apr 2022.

EC. European Commission (EC), JRC Science for Policy Report, Rauscher H, Roebben G, Mech A, Gibson N, Kestens V, Linsinger TPJ, Riego Sintes J. An overview of concepts and terms used in the European Commission’s definition of nanomaterial. JRC, Ispra: European Commission; 2019. https://doi.org/10.2760/459136. ISBN 978-92-79-99660-3.

Book  Google Scholar 

EMA. European Medicines Agency (EMA), Papaluca M. Way forward. 1st International Workshop on Nanomedicine. London, United Kingdom; 2010. https://www.ema.europa.eu/en/documents/presentation/presentation-way-forward-marisa-papaluca-ema_en.pdf. Accessed 3 Apr 2022.

Pita R, Ehmann F, Papaluca M. Nanomedicines in the EU-Regulatory Overview. AAPS J. 2016;18(6):1576–82. https://doi.org/10.1208/s12248-016-9967-1.

Article  CAS  PubMed  Google Scholar 

EC. European Commission (EC) - Commission Recommendation on the definition of nanomaterial (2022). 2022. https://ec.europa.eu/environment/chemicals/nanotech/pdf/C_2022_3689_1_EN_ACT_part1_v6.pdf. C(2022) 3689 final. Accessed 13 Oct 2022.

HC. Health Canada (HC) - Policy Statement on Health Canada's Working Definition for Nanomaterial. 2011. https://www.canada.ca/en/health-canada/services/science-research/reports-publications/nanomaterial/policy-statement-health-canada-working-definition.html. Accessed 3 Apr 2022.

ISO. International Organization for Standardization (ISO) - Definition of nanomaterial. 2017. https://www.iso.org/obp/ui/#iso:std:iso:ts:21623:ed-1:v1:en:term:3.10. Accessed 3 Apr 2022.

Boverhof DR, Bramante CM, Butala JH, Clancy SF, Lafranconi M, West J, Gordon SC. Comparative assessment of nanomaterial definitions and safety evaluation considerations. Regul Toxicol Pharmacol. 2015;73(1):137–50. https://doi.org/10.1016/j.yrtph.2015.06.001.

Article  CAS  PubMed  Google Scholar 

EC. European Commission (EC), JRC Technical Reports - Bremer S, Halamoda-Kenzaoui B, Borgos SE. Identification of regulatory needs for nanomedicines: 1st EU-NCL survey with the “Nanomedicine” working group of the international pharmaceutical regulators. 2016. http://publications.jrc.ec.europa.eu/repository/bitstream/JRC103557/170412-report-identification_regulatory_needs_nanomedicines-final_05.12.16_online_version.pdf. Accessed 3 Apr 2022.

EvoNano. Evolvable platform for programmable nanoparticle-based cancer therapies (EvoNano). 2022. https://evonano.eu/. Accessed 3 Apr 2022.

Allan J, Belz S, Hoeveler A, Hugas M, Okuda H, Patri A, Rauscher H, Silva P, Slikker W, Sokull-Kluettgen B, Tong W, Anklam E. Regulatory landscape of nanotechnology and nanoplastics from a global perspective. Regul Toxicol Pharmacol. 2021;122:104885. https://doi.org/10.1016/j.yrtph.2021.104885.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Isles MP. Nanomedicines and Nanosimilars - Why a Robust Centralised Regulatory Framework Is Essential to Enhance Patient Safety. Front Pharmacol. 2022;12:787239. https://doi.org/10.3389/fphar.2021.787239.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nanotechnology N. Nanomedicine and the COVID-19 vaccines. Nat Nanotechnol. 2020;2020(15):963. https://doi.org/10.1038/s41565-020-00820-0.

Article  CAS